Table 1 Outcomes and follow-up periods
Studies | Outcomes reported | Follow-up periods | DDC versus control group |
|---|---|---|---|
CURRENT OASIS 7 [11] | CV death, MI, or stroke (MACE); CV death, MI, stroke, total mortality, TIMI major bleeding, minor bleeding, fatal bleeding, intracranial bleeding | 30Â days | DDC versus SDAPT |
ACCEL AMI [12] | Minor bleeding | 30Â days | DDC versus SDAPT |
OPTIMUS2007 [13] | Bleeding complications | 30Â days | DDC versus SDAPT |
CREATIVE [14] | MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding | 18Â months | DDC versus SDAPT |
Chen2017 [15] | MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding | 12Â months | DDC versus SDAPT |
Khatri2013 [16] | Composite efficacy outcomes, any bleeding event | 23Â months | DDC versus prasugrel |
OPTIMUS3 [17] | Major and minor TIMI defined bleeding, adverse drug events | 7Â days | DDC versus prasugrel |
PRINCIPLE TIMI 44 [18] | TIMI major and minor bleeding, minor bleeding, hemorrhagic adverse events, MI | 2Â weeks | DDC versus prasugrel |
Tailor2014 [19] | MACE, MI, ST, CV death, stroke | 1Â month and 571Â days | DDC versus prasugrel |
Chen2017 [15] | MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding | 12Â months | DDC versus ticagrelor |
Wu2017 [20] | MACE, minimal bleeding, minor bleeding | 30Â days | DDC versus ticagrelor |
ACCEL AMI [12] | Minor bleeding | 30Â days | DDC versus TAPT |
ACCEL DM [21] | Bleeding event | 30Â days | DDC versus TAPT |
CREATIVE [14] | MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding | 18Â months | DDC versus TAPT |
Ha2013 [22] | MACE | 1Â month | DDC versus TAPT |
HOST ASSURE [23] | MACE, cardiac death, MI, stroke, ST, all-cause death, TLR, TVR, PLATO minor bleeding | 30Â days | DDC versus TAPT |
Jeong2009 [24] | MACE, major and minor bleeding | 30Â days | DDC versus TAPT |